UBS Reiterates a 'Neutral' on Rite-Aid (RAD); A Few Longer-Term Tailwinds, But Staying Sidelined For Now
Tweet Send to a FriendGet Alerts RAD Hot Sheet
Price: $2.79 +7.31%
Rating Summary:
5 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
5 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade RAD Now!
UBS reiterates a 'Neutral' on Rite-Aid (NYSE: RAD) price target of $1.35 (from $1.80).
Analyst, Jason DeRise, said, "RAD shares have underperformed the market by ~30% in the last 3mos. Despite this, we believe the best place for shareholders is the sidelines because RAD’s fundamental performance has trended weaker than expected. Though its business remains challenged; RAD has at least two industry tailwinds to its back to support its very gradual turnaround: (1) aging population and (2) the generic wave. If RAD can pay down its debt over the long term, we believe its equity value can grow materially. For now, we think there is too much uncertainty to discount this LT bull case into today’s price."
DeRise also sees sustained improvements in prescription sales as the Walgreen (NYSE: WAG) / Express Scripts (Nasdaq: ESRX) battle continues. However, the most recent report was negative from RAD, which explains the Neutral rating. Because of the current embattled environment (with RAD not capitalizing as quickly), DeRise cuts FY13 EPS loss from (0.18) to (0.22) and FY14 from (0.04) to (0.08).
For an analyst ratings summary and ratings history on Rite-Aid click here. For more ratings news on Rite-Aid click here.
Shares of Rite-Aid closed at $1.24 yesterday, with a 52 week range of $0.85-$2.12.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jason DeRise, said, "RAD shares have underperformed the market by ~30% in the last 3mos. Despite this, we believe the best place for shareholders is the sidelines because RAD’s fundamental performance has trended weaker than expected. Though its business remains challenged; RAD has at least two industry tailwinds to its back to support its very gradual turnaround: (1) aging population and (2) the generic wave. If RAD can pay down its debt over the long term, we believe its equity value can grow materially. For now, we think there is too much uncertainty to discount this LT bull case into today’s price."
DeRise also sees sustained improvements in prescription sales as the Walgreen (NYSE: WAG) / Express Scripts (Nasdaq: ESRX) battle continues. However, the most recent report was negative from RAD, which explains the Neutral rating. Because of the current embattled environment (with RAD not capitalizing as quickly), DeRise cuts FY13 EPS loss from (0.18) to (0.22) and FY14 from (0.04) to (0.08).
For an analyst ratings summary and ratings history on Rite-Aid click here. For more ratings news on Rite-Aid click here.
Shares of Rite-Aid closed at $1.24 yesterday, with a 52 week range of $0.85-$2.12.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Wells Fargo Upgrades Rosetta Resources (ROSE) to Outperform, Shares Attractive
- Compass Point Boosts Numbers on RLJ Lodging Trust (RLJ)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
